Drugs / S227928
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06563804 | Feb → Oct 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia | Servier Bio-Innovation LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S227928 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06563804 ↗ |
| Route | Intravenous | “For administration via intravenous (IV) infusion” NCT06563804 ↗ |
| Target | CD74 | “an Anti-CD74 Antibody-Drug Conjugate” NCT06563804 ↗ |